anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a foam having a cosmetic composition dipped therein. The foam is produced by mixing and foaming ether-based polyol and ester-baed polyol to be molded into a urethane foam. According to the present invention, the foam has good cushioning properties,air permeability, yielding properties, softness, flexibility, humidity and heat resistance, and hydrolysis resistance with a cosmetic composition, and has very excellent strength and oil resistance with a cosmetic composition. Accordingly, a cosmetic composition can be smoothly filled and can be uniformly dipped for a long time. When a cosmetic composition is applied, a suitable amount of the cosmetic composition is discharged. Even after the cosmetic composition is contained, excellent durability can be maintained. Consequently, when the foam having a cosmetic composition dipped therein is used, even a liquid cosmetic composition can be conveniently carried, and a user can conveniently put a makeup even in an outdoor place.
A computer program product is provided. The computer program product includes processor executable code for an integration tracking engine. The processor executable code is stored on a non-transitory computer readable medium. The processor executable code is executed by a processor to cause the integration tracking engine to requisition users to generate corresponding user profiles and receive sample data and tracking information for samples corresponding to the users from a test site. The integration tracking engine also generates a manifest that provides automatic sample tracking of the samples as the samples move between the test site and a lab and that provides automatic sample tracking of a processing status of the one or more samples. The integration tracking engine also provides, to the users, test results that are generated by the lab and corresponding to medical orders.
BACKGROUND: Research and monitoring of human resources available for vision rehabilitation services has been a neglected area of work in the past. This study aims to offer an overview of the vision rehabilitation workforce available in Italy, in order to profile the distribution and number of human resources for vision rehabilitation.
METHODS: Data on the available vision rehabilitation professionals were collected from the yearly report on the state of implementation of policies relating to the prevention of blindness, education and vision rehabilitation, according to a law which was passed by the Italian Ministry of Health, Department of Health Prevention. The report presents a review of all professional workers dealing with low vision rehabilitation centers in Italy between January 2005 and December 2019. Data on the distribution and type of services of government-supported low vision centers across the country were also obtained and examined.
RESULTS: Of the 289 low vision rehabilitation workers in 2019, 28% were ophthalmologists, 31% orthoptists, 19% psychologists, 17% nurses and 5% social workers. The health workforce densities across the Italian regions ranged from 1.62 to 0.12 per 100.000. The density of vision rehabilitation workers showed a no growing trend from 2006 to 2015. During the study period, it was found a weak but statistically significant association of workforce density with the number of government-supported low vision centers across the Italian territory (r2 = 0.3, p < 0.05). The vision rehabilitation workforce was not associated with the number of low vision patients who accessed to a vision rehabilitation center (r2 = 0.05, p < 0.0001).
DISCUSSION: A critical review has identified the following national situation: need-based shortages of workers in the vision rehabilitation service sector, as well as deficiencies in data sources. Based on our results, we would recommend increasing the development of human resources trained and dedicated to vision rehabilitation and improve data collection and analysis; provide structural enhancements, across all service levels. These considerations may contribute to the enhancement of policy decisions in order to guarantee an adequate vision rehabilitation workforce and meet national rehabilitation needs. Furthermore, this analysis should be used as a lesson learned by other countries, as low-income ones, in order to develop vision rehabilitation services.
Neuropathic pain is a type of pain that results from nerve damage and is characterized by an abnormal hypersensitivity to harmless as well as harmful stimuli. This type of pain is extremely difficult to manage, fails to respond to standard analgesic medications or interventions, and often gets worse instead of better over time. Current approved therapeutic agents often have intolerable side effects and limited efficacy. Thus, there is an urgent need to develop safe and effective drugs to treat neuropathic pain.

Study DTCL100 will be conducted at multiple centers and will enroll patients that have advanced cancer AND neuropathic pain that has not responded well to previous treatment. Eighteen patients will be randomly assigned to receive up to 8 doses of active drug (KRN5500) or placebo. A maximum of 8 doses will be administered weekly over a 10 week period. Patients are encouraged to complete at least 4 treatment visits before a decision is made to complete the full 10 weeks of treatment and the 1 month followup period.
Neural networks are constructed (programmed), and trained on historical data relating the (i) alleles, to the (ii) clinical responses, of a large number of patients. The trained neural networks show which alleles are, in combination, of practical pertinence to a wide range of biological, social and clinical variables. The trained neural networks may be exercised to predict (i) the responses of populations to different therapies, and (ii) the occurrences of adverse reactions. The trained neural networks are exercised in consideration of the genomic data of an individual patient to predict the response(s) of the individual patient to, most particularly usefully, any of (1) optimal drug dosage, (2) drug dosage sensitivity, (3) expected therapeutic outcome(s), and/or (4) adverse side effects may can be predicted in consideration of the alleles of the patient. Both the human and the economic costs of both optimal and sub-optimal drug therapies may be extrapolated from the exercise of various optimized and trained neural networks. The preferred neural network mapping is on (i) inputs that have underdone “householding”, meaning that multiple genes are treated as a single unit, by (ii) use of a Genetic Algorithm (GA) that is “rolled”, meaning that mapping transpires in neural networks organized hierarchically in stages so as to relate a typically vast amount genomic data as neural networks inputs to but very little clinical data as the outputs of a final, root node, neural network.
The invention relates to a process for the preparation of a mixture of a 6-deoxy tetracycline and a 6-epi-6-deoxytetracycline which includes the step of hydrogenating a compound of formula <FORM:0995032/C2/1> <FORM:0995032/C2/2> wherein Y may be hydrogen or hydroxyl, X may be hydrogen, chloro, bromo or iodo, X1 may be hydrogen, amino or lower alkanoylamino of 1-6 carbon atoms, X2 may be hydrogen or nitro and Z is chloro or fluoro or an acid addition salt or polyvalent metal complex salt thereof in the presence of a noble metal catalyst till reduction of the methylene group and when Z is a chloro group it being replaced by hydrogen and also to the compounds which are 7 and/or D-ring substituted 6-epi-d-deoxy-5-oxytetracyclines in which the substituent is chloro, hydrogen, nitro, amino or lower alkanoylamino containing 1-5 carbon atoms, the 11a chloro or fluoro derivatives thereof and acid addition salts, metal salts and polyvalent metal salt complexes thereof. Specified noble metal catalysts are rhodium, palladium, platinum, rhenium and ruthenium and their oxides and chlorides.  Rhodium permits retention of a 7-halo atom.  11a fluoro atoms may be removed and 11a-chloro and -fluoro, 7-halo and 7 or 9 nitro atoms and groups may be introduced into the products of the process of the invention by the processes described in Specification 995,031.  Diazotization of 9-amino groups followed by a Sandmeyer reaction enables halo and nitrile groups to be introduced into the 9-position of said products. Preparation of 7-azo compounds from 7 halo compounds followed by catalytic hydrogenation leads to the introduction of 7-amino groups. Specified acid addition salts are those formed with hydraulic, hydroiodic, hydrobromic, phosphoric, metaphosphoric, nitric, sulphuric, tartaric, acetic, citric, malic, benzoic, glycollic, gluconic, gulonic, succinic p-toluene sulphonic perchloric, and sulphosalicylic acids.  Metals salts specified are those formed with alkali and alkaline earth metals.  Metal salt complexes specified are those formed with salts of the metals calcium, cobalt, magnesium, tin, zinc, cadmium, barium, silver, strontium, palladium, manganese, cerium, aluminium, titanium, platinum, vanadium, lead, chromium and nickel.  The 6-epi-6-deoxy tetracycline products of the invention may be used in pharmaceutical and veterinary compositions for enteral, parenteral and topical application as capsules, tablets, solutions, suspensions and vials sterilized with ethylene oxide.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to cosmetics, particularly to antiperspirants. The invention is characterised by a stable absorption pharmaceutical preparation for percutaneous introduction of a primary medicine, with the exception of selegelin and selegelin hydrochloride which is exposed to reduced cohesive forces of an adhesive layer even in the presence of the sweat component because of transpiration and which is free from cohesive destruction and residual adhesive when the preparation is removed. The absorption pharmaceutical preparation for percutaneous introduction contains: a substrate; and an adhesive layer containing an adhesive, metal chloride and a skin-absorbable drug, with the exception of selegelin and selegelin hydrochloride where the adhesive layer is cross-linked. ^ EFFECT: improved efficacy of the preparation. ^ 8 cl, 18 ex
PURPOSE OF REVIEW: Increasing life expectancy among patients with advanced cancer has placed a greater emphasis on optimizing pain control and quality of life. Concurrently, significant advancements in radiotherapy for bone metastases have permitted for dose escalation strategies such as stereotactic radiotherapy. This review aims to provide updated information on the management of bone metastases in light of these developments.
RECENT FINDINGS: We reviewed recent studies regarding the role and details of external beam radiotherapy for bone metastases, with emphasis on differences by treatment site as well as intention (palliative versus ablative for oligometastases). Conventional palliative radiotherapy remains a mainstay of management. While stereotactic radiotherapy may augment durability of pain relief and even survival time, there are significant questions remaining regarding optimal dosing and patient selection. Radiotherapy for bone metastases continues to evolve, particularly with increasing use of stereotactic radiotherapy. Future studies are needed to clarify optimal dose, fractionation, modality, and patient selection criteria among different radiotherapy approaches.
There is a dearth of information on the mechanisms, and potential moderators, of physical activity (PA) intervention effectiveness. Understanding the mechanisms of PA change will aid in successful intervention development while understanding moderators will allow a matching of intervention components to individual needs of particular populations. To definitively understand mechanisms and moderators of behavior change it is necessary to develop theory-based interventions that include specific strategies that target proposed mechanisms of change while monitoring the proposed mediating and moderating variables prior to and following intervention. This proposal highlights the use of the Ecological Model of Physical Activity (EMPA) as a theoretical guide to strategy development. The EMPA highlights the necessity to address individual (biological \& psychosocial) and environmental variables (e.g., PA resource accessibility) when developing and implementing interventions. Health care patients who have been referred for a treadmill cardiovascular stress test-but do not present abnormal ECG or chest pain during testing-will be will be stratified by diagnosis of low heart rate recovery, a potential biological moderator of intervention effectiveness. To detect the potential independent and combined effects of individual motivation and environmental accessibility we will conduct a randomized 2X2 factorial trial to test proposed mediators of effectiveness. Participants (n=500) will be randomized to an individual (I), environmental (E) , combination (I+E), or matched contact nutrition control. All intervention conditions will include a CD-ROM session, 3 tailored mail, and 3 tailored automated telephone follow-ups over a 6-month period. We will assess the reach, effectiveness, clinician adoption, and staff implementation of these interventions, individually, in combination, and when compared to controls among an understudied and high need population-individuals who are at an elevated risk, but have not yet suffered a serious cardiac event (approximately 3,000,000 individuals/year in the US). The results of this project will identify the causal, and potentially additive, relationships of environmental and individual mediators of PA change and allow the examination of potential biological moderators of effectiveness. Because intervention typically effects decrease over time and studies do not address setting-related issues necessary to ensure sustainability of delivery at the organizational level we will determine the maintenance of intervention effects on causal mechanisms and PA, 6 \& 12 months following intervention. The interventions will be developed for delivery within the regular scope of treadmill stress testing by typical medical staff and cost of delivery will be assessed for each intervention condition. This project uniquely utilizes methods that will facilitate institutionalization of the intervention components following the successful completion of the trial and potential adoption of the intervention in other health care settings.
BACKGROUND: Many of the drugs used for the treatment and alleviation of symptoms in cancer patients are known to inhibit or induce cytochrome P450 (CYP). Therefore, it is important to pay attention to the drug interactions of opioid analgesics that are metabolized by CYPs, because for example when using oxycodone metabolized by CYP3A4, it is possible that the effect will be attenuated or enhanced by the concomitant use of drugs that induce or inhibit CYP3A4. Aprepitant, an antiemetic drug used in many patients receiving anticancer drugs, is known as a moderate competitive inhibitor of CYP3A4. We experienced a case of respiratory depression caused by opioids, which was suspected to be caused by a drug interaction with antiemetics especially aprepitant.
CASE DESCRIPTION: The patient was a 72-year-old man. He had been treated with continuous oxycodone infusion for perianal pain associated with the rectal invasion of prostate cancer. No comorbidities other than renal dysfunction were observed. Oxycodone treatment was started at 48 mg/day, and was increased to 108 mg/day, and then the pain decreased. Once the pain was controlled, chemotherapy was planned. Antiemetics (dexamethasone, palonosetron, and aprepitant) were administered before anticancer drug administration. Approximately 3 hours after antiemetics administration and before the administration of the anticancer drugs, a ward nurse noticed that oversedation and respiratory depression had occurred. When the patient was called, he immediately woke up and was able to talk normally, so the anticancer drugs were administered as scheduled. About 2 hours after the nurse noticed oversedation, the attending physician reduced the dose of oxycodone infusion to 48 mg/day. After that, his drowsiness persisted, but his respiratory condition improved. Despite reducing the dose of oxycodone to less than half, the pain remained stable at numeric rating scale (NRS) 0-1, without the use of a rescue dose. The patient was discharged from the hospital 36 days after the administration of anticancer drugs, without any problems.
CONCLUSIONS: The cause of respiratory depression in this case was thought to be a combination of factors, including drug interactions between oxycodone and antiemetics, and oxycodone accumulation due to renal dysfunction.
Participants in the control group will be asked to identify an unfavourable behaviour that they want to change at the baseline but, rather than brief MI interviews delivered face-to-face, received generic health advice consultations on the selected unfavourable behaviour that lasted approximately five to ten minutes. Each participant will receive a self-help smoking cessation booklet titled Be Smart, Quit Smoking! published by the Hong Kong Council on Smoking and Health with information about the negative health consequences of smoking, reasons to quit, strategies for quitting, and smoking cessation services available in Hong Kong along with a public quitline number (specifically, 1833183). Those who express the intention to quit at follow-ups will receive usual smoking cessation support.
Magnetic or non-magnetic microspheres, populations of magnetic or non-magnetic microspheres, and methods for forming magnetic or non-magnetic microspheres are provided. One microsphere configured to exhibit fluorescent and magnetic properties includes a core particle and a monolayer of magnetic particles coupled to a substantial portion of a surface of a core particle. About 60% to about 90% of a surface of a core particle is covered by the monolayer of magnetic particles. The microsphere also includes an outer polymer layer surrounding or encapsulating both the monolayer of magnetic particles and the core particle. One population of magnetic or non-magnetic microspheres is configured to exhibit fluorescent and magnetic properties includes two or more subsets of magnetic fluorescent microspheres. The two or more subsets of microspheres are configured to exhibit different fluorescent and/or magnetic properties. Individual microspheres in the two or more subsets are configured as described herein.
The sensitization and hypertonicity of visceral afferents are highly relevant to the development and progression of cardiovascular and respiratory disease states. In this review, we described the evidence that the inflammatory process regulates visceral afferent sensitivity and tonicity, affecting the control of the cardiovascular and respiratory system. Some inflammatory mediators like nitric oxide, angiotensin II, endothelin-1, and arginine vasopressin may inhibit baroreceptor afferents and contribute to the baroreflex impairment observed in cardiovascular diseases. Cytokines may act directly on peripheral afferent terminals that transmit information to the central nervous system (CNS). TLR-4 receptors, which recognize lipopolysaccharide, were identified in the nodose and petrosal ganglion and have been implicated in disrupting the blood-brain barrier, which can potentiate the inflammatory process. For example, cytokines may cross the blood-brain barrier to access the CNS. Additionally, pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α and some of their receptors have been identified in the nodose ganglion and carotid body. These pro-inflammatory cytokines also sensitize the dorsal root ganglion or are released in the nucleus of the solitary tract. In cardiovascular disease, pro-inflammatory mediators increase in the brain, heart, vessels, and plasma and may act locally or systemically to activate/sensitize afferent nervous terminals. Recent evidence demonstrated that the carotid body chemoreceptor cells might sense systemic pro-inflammatory molecules, supporting the novel proposal that the carotid body is part of the afferent pathway in the central anti-inflammatory reflexes. The exact mechanisms of how pro-inflammatory mediators affects visceral afferent signals and contribute to the pathophysiology of cardiovascular diseases awaits future research.
Conditioned pain modulation and exercise-induced hypoalgesia reflect inhibitory pain controls emanating from the brain. The aim of this study was to compare the extent of pain inhibition from exercise-induced hypoalgesia (isometric wall squat), conditioned pain modulation (cold-water immersion), and their combination (wall squat followed by cold water in fixed order) in healthy pain-free adults. Sixty-one participants (median age 21 years) completed 3 sessions (wall-squat, cold-water, and combined) in random order. Sessions were separated by at least a week. In each session, pressure-pain thresholds, single-pinprick-pain ratings, and pinprick-temporal summation of pain (the fifth minus the first) were obtained at quadriceps, forearms, and forehead, before and after wall squat and/or cold water. Each intervention inhibited pain to pressure (partial η2 = .26) and single pinprick (partial η2 = .16) to a similar extent; however, pressure-pain inhibition was negligible in the forehead. After adjusting for age and sex, single-pinprick-pain inhibition in the forehead induced by wall squat was associated with that induced by cold water (adjusted R2 = .15; P = .007), and stronger pain inhibition was predicted by a higher thigh-pain rating to wall squat (adjusted R2 = .10; P = .027). Neither intervention affected pinprick-temporal summation of pain. Together, the findings suggest that pain-inhibitory effects of exercise-induced hypoalgesia and conditioned pain modulation may overlap when exercise is at least moderately painful (6/10 intensity). Pressure pain in body regions remote from the exercised or conditioned sites may be weakly modulated. PERSPECTIVE: The current findings suggest that pain-inhibitory effects induced by painful wall squat and by cold-water immersion may overlap. The magnitude of pain inhibition in the forehead remote from the exercised thigh or the conditioned foot appears smaller, which could be examined further in future research.
PROBLEM TO BE SOLVED: To obtain a retinoid preparation with reduced irritation and enhanced safety by formulating a retinoid in specific porous particles. SOLUTION: In a medicinal preparation containing solid and water-insoluble fine particles, porous matrix particles holding a retinoid in the pores are formulated or the retinoid is formulated as a particle suspension. The solid fine particles have an average particle size of 5-100μm, a whole pore capacity of 0.1-2.0cc/g and a surface area of 20-350m<2> /g. The solid particles are preferably made of a crosslinked polymer, for example, styrene-divinylbenzene copolymer or a methyl methacrylate-ethylene glycol de(methacrylate) copolymer. The retinoid compound is particularly selected from among retinol, retinal, retinoic acid and the like and its amount in the composition is 5-60wt.%. Further, addition of a chelating agent and an antioxidant improves the stability of the preparation.
1. Technical Result Increase in treatment efficiency.          2. Essence A pharmaceutical preparations comprises one of the botulinum neurotoxins of Clostridium botulinium –of types A, B, C, D, E, F or G or a mixture of two or more of these neurotoxins, in which the neurotoxins do not contain the complexing proteins which, together with the neurotoxins, naturally form the botulinum neurotoxin complexes.         3. Field of Application Medicine.